Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN
RESEARCH TOOLSreports
Holding DAWN?
Track your performance easily
DAWN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.76 - $18.07
Previous Close$15.01
Volume234.04K
Average Volume (3M)994.40K
Market Cap
$1.30B
Enterprise Value$955.61M
Total Cash (Recent Filing)$361.87M
Total Debt (Recent Filing)$190.00K
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Oct 30, 2024EPS Estimate
-$0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.93
Shares Outstanding98,310,000
10 Day Avg. Volume1,059,251
30 Day Avg. Volume994,398
Standard Deviation0.33
R-Squared0.05
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)4.81
Price to Sales (P/S)180.13
Price to Cash Flow (P/CF)-7.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue116.65
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.52
Forecast
1Y Price Target
$36.56Price Target Upside147.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Day One Biopharmaceuticals News
PremiumCompany Announcements
Day One Biopharmaceuticals Reveals Updated Corporate StrategyBulls Say, Bears Say
Bulls Say
Financial PerformanceDay One Biopharmaceuticals reported impressive net sales of $8.2 million for Ojemda, significantly surpassing expectations and showcasing strong early market performance.
Market AdoptionOjemda is anticipated to be used in up to 60% of pediatric low-grade glioma patients at its peak, indicating strong market acceptance and potential growth.
Strategic DevelopmentsThe acquisition of DAY301 and the shift in investment strategy positions Day One Biopharmaceuticals for productive growth and diversification in its drug development pipeline.
Bears Say
Clinical TrialsDiscontinuation of the FIRELIGHT-1 trial (pimasertib/tovorafenib combo study in MAPK-altered tumors).
Program DiscontinuationDiscontinuation of pimesertinib program takes away $2/share from the valuation model.
Stock ValuationThe capital raise led to a price target adjustment down to $32 from $33.
---
Ownership Overview
20.37% Insiders
15.06% Mutual Funds
0.25% Other Institutional Investors
52.05% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DAWN FAQ
What was Day One Biopharmaceuticals’s price range in the past 12 months?
Day One Biopharmaceuticals lowest stock price was $9.76 and its highest was $18.07 in the past 12 months.
What is Day One Biopharmaceuticals’s market cap?
Currently, no data Available
When is Day One Biopharmaceuticals’s upcoming earnings report date?
Day One Biopharmaceuticals’s upcoming earnings report date is Oct 30, 2024 which is in 9 days.
How were Day One Biopharmaceuticals’s earnings last quarter?
Day One Biopharmaceuticals released its earnings results on Jul 30, 2024. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.751 by $0.701.
Is Day One Biopharmaceuticals overvalued?
According to Wall Street analysts Day One Biopharmaceuticals’s price is currently Undervalued.
Does Day One Biopharmaceuticals pay dividends?
Day One Biopharmaceuticals does not currently pay dividends.
What is Day One Biopharmaceuticals’s EPS estimate?
Day One Biopharmaceuticals’s EPS estimate is -$0.61.
How many shares outstanding does Day One Biopharmaceuticals have?
Day One Biopharmaceuticals has 87,760,450 shares outstanding.
What happened to Day One Biopharmaceuticals’s price movement after its last earnings report?
Day One Biopharmaceuticals reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.751. Following the earnings report the stock price went down -1.107%.
Which hedge fund is a major shareholder of Day One Biopharmaceuticals?
Among the largest hedge funds holding Day One Biopharmaceuticals’s share is RA Capital Management. It holds Day One Biopharmaceuticals’s shares valued at 108M.
---
Day One Biopharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.56 (147.70% Upside)
$36.56 (147.70% Upside)
Blogger Sentiment
Bullish
DAWN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 7.8%
Last 30 Days ▲ 7.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
45.58%
12-Months-Change
Fundamentals
Return on Equity
-45.71%
Trailing 12-Months
Asset Growth
-11.16%
Trailing 12-Months
Company Description
Day One Biopharmaceuticals
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
---
DAWN Stock 12 Month Forecast
Average Price Target
$36.56
▲(147.70% Upside)
Technical Analysis
Best Analysts Covering DAWN
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
-1.55%
reiterated a buy rating 3 months ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of -1.55% per trade.
---